Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Aug;69(4):364–377. doi: 10.1016/j.curtheres.2008.08.005

Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study

Shinji Sakaue 1,*, Mitsunori Kamigaki 1, Haruhiko Yoshimura 2, Masaharu Nishimura 1
PMCID: PMC3969936  PMID: 24692813

Abstract

Background: Insulin resistance is a critical aspect of the pathophysiology of type 2 diabetes mellitus and is also associated with other risk factors for cardiovascular disease (eg, dyslipidemia and hypertension). Accordingly, insulin resistance is a possible target for lowering plasma glucose concentration and preventing diabetic macroangiopathy. Biguanides, such as metformin, and thiazolidinediones (TZDs), such as pioglitazone, improve insulin resistance.

Objectives: The aims of this study were to assess the effects of replacing a biguanide with a TZD on glycemic control in patients with poorly controlled type 2 diabetes mellitus, and also to identify the factors affecting interpatient variation in the effects of treatment change.

Methods: This was a 12-week, open-label, prospective study in which previously prescribed metformin (500 or 750 mg/d) was replaced with pioglitazone (15 or 30 mg/d) in patients with poorly controlled type 2 diabetes mellitus. Patients with a glycosylated hemoglobin (HbA1c) concentration >7% despite treatment with diet, exercise, and hypoglycemic agents other than TZDs were eligible for the study. Patients who never received TZDs were also eligible for inclusion. Vital signs, metabolic parameters, and arterial stiffness were assessed at baseline and after 12 weeks of treatment with pioglitazone. The primary end point was change in HbA1c concentration after replacing metformin with pioglitazone. Tolerability was assessed by medical history, physical examination, and laboratory tests (aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase).

Results: Twenty-one Japanese patients (15 women, 6 men; mean [SD] age, 61.8 [8.4] years; body mass index, 25.5 [3.0] kg/m2) were included in the study. HbA1c concentration was not significantly changed from baseline after 12 weeks of pioglitazone treatment (8.0% [0.7%] vs 8.2% [0.7%]). Fasting plasma glucose (FPG) concentration also was not significantly changed after the replacement of treatment (156 [27] vs 144 [30] mg/dL). In addition, the resistin concentration did not change significantly from baseline after 12 weeks of pioglitazone treatment (6.6 [3.8] vs 6.4 [3.6] ng/mL). In contrast, significant improvement from baseline was observed in triglyceride (TG) concentrations (157 [109] vs 117 [68] mg/dL; P = 0.003), high-density lipoprotein cholesterol (HDL-C) (55 [12] vs 61 [16] mg/dL; P = 0.016), remnant-like particle cholesterol (6.6 [6.0] vs 5.3 [3.5] mg/dL; P = 0.048), and serum adiponectin (8.8 [4.3] vs 23.3 [11.7] μg/mL; P < 0.001). Pulse wave velocity was also significantly improved (1730 [361] vs 1622 [339] m/sec; P = 0.009). Changes in HbA1c were significantly correlated with serum fasting insulin concentration at baseline in the patients not receiving insulin preparations (r = -0.635, P = 0.013). The percentage change in serum adiponectin concentration was correlated with the percentage changes in HbA1c and FPG concentrations (HbA1c, r = -0.518, P = 0.019; FPG, r = -0.594, P = 0.006). Body weight was significantly increased after treatment (62.6 [11.9] vs 65.5 [12.2] kg; P < 0.001). Mild edema was reported in 5 patients. One patient discontinued treatment due to an increase in serum creatine kinase activity to ~6.6 times the upper limit of normal.

Conclusions: Replacement of metformin with pioglitazone did not produce significant differences in HbA1c and FPG concentrations from baseline after 12 weeks of treatment in these patients with poorly controlled type 2 diabetes mellitus. However, the replacement was effective in a subset of patients whose serum insulin concentrations were high or whose serum adiponectin concentrations were sensitive to TZDs. In addition, the replacement was associated with significant improvements in TG, HDL-C, serum adiponectin concentration, pulse wave velocity, and body weight increase from baseline.

Key words: insulin resistance, metformin, pioglitazone, Japanese

Full Text

The Full Text of this article is available as a PDF (667.8 KB).

References

  • 1.Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346. doi: 10.1016/S0140-6736(05)61032-X. [DOI] [PubMed] [Google Scholar]
  • 2.Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab. Diabetes Obes Metab. 2005;2005;77:675–691. 769. doi: 10.1111/j.1463-1326.2005.00497.x. [published correction appears in. ] [DOI] [PubMed] [Google Scholar]
  • 3.Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA. 2002;287:360–372. doi: 10.1001/jama.287.3.360. [DOI] [PubMed] [Google Scholar]
  • 4.Inzucchi SE, Maggs DG, Spollett GR. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867–872. doi: 10.1056/NEJM199803263381303. [DOI] [PubMed] [Google Scholar]
  • 5.Zhou G, Myers R, Li Y. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174. doi: 10.1172/JCI13505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Okuno A, Tamemoto H, Tobe K. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101:1354–1361. doi: 10.1172/JCI1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Pavo I, Jermendy G, Varkonyi TT. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:1637–1645. doi: 10.1210/jc.2002-021786. [DOI] [PubMed] [Google Scholar]
  • 8.Schernthaner G, Matthews DR, Charbonnel B, Quartet Study Group Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J Clin Endocrinol Metab. J Clin Endocrinol Metab. 2004;2005;8990:6068–6076. 746. doi: 10.1210/jc.2003-030861. [published correction appears in. ] [DOI] [PubMed] [Google Scholar]
  • 9.Suter SL, Nolan JJ, Wallace P. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193–203. doi: 10.2337/diacare.15.2.193. [DOI] [PubMed] [Google Scholar]
  • 10.Kuehnle HF. New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes. 1996;104:93–101. doi: 10.1055/s-0029-1211429. [DOI] [PubMed] [Google Scholar]
  • 11.Kawamori R, Kadowaki T, Onji M, PRACTICAL Study Group Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan. Diabetes Res Clin Pract. 2007;76:229–235. doi: 10.1016/j.diabres.2006.08.017. [DOI] [PubMed] [Google Scholar]
  • 12.Chan JC, Deerochanawong C, Shera AS. Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective. Diabetes Res Clin Pract. 2007;75:255–266. doi: 10.1016/j.diabres.2006.06.023. [DOI] [PubMed] [Google Scholar]
  • 13.Kawai T, Funae O, Shimada A. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Intern Med. 2008;47:1181–1188. doi: 10.2169/internalmedicine.47.0969. [DOI] [PubMed] [Google Scholar]
  • 14.World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–3045. [PubMed] [Google Scholar]
  • 15.Examination Committee of Criteria for ‘Obesity Disease’ in Japan. Japan Society for the Study of Obesity New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–992. doi: 10.1253/circj.66.987. [DOI] [PubMed] [Google Scholar]
  • 16.Maeda N, Takahashi M, Funahashi T. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–2099. doi: 10.2337/diabetes.50.9.2094. [DOI] [PubMed] [Google Scholar]
  • 17.Yang WS, Jeng CY, Wu TJ. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25:376–380. doi: 10.2337/diacare.25.2.376. [DOI] [PubMed] [Google Scholar]
  • 18.Hirose H, Kawai T, Yamamoto Y. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51:314–317. doi: 10.1053/meta.2002.30506. [DOI] [PubMed] [Google Scholar]
  • 19.Jung HS, Youn BS, Cho YM. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism. 2005;54:314–320. doi: 10.1016/j.metabol.2004.05.019. [DOI] [PubMed] [Google Scholar]
  • 20.Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. doi: 10.1210/er.2005-0005. [DOI] [PubMed] [Google Scholar]
  • 21.Miyazaki Y, Mahankali A, Wajcberg E. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:4312–4319. doi: 10.1210/jc.2004-0190. [DOI] [PubMed] [Google Scholar]
  • 22.Kubota N, Terauchi Y, Kubota T. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006;281:8748–8755. doi: 10.1074/jbc.M505649200. [DOI] [PubMed] [Google Scholar]
  • 23.Satoh N, Ogawa Y, Usui T. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493–2499. doi: 10.2337/diacare.26.9.2493. [DOI] [PubMed] [Google Scholar]
  • 24.Cruickshank K, Riste L, Anderson SG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function? Circulation. 2002;106:2085–2090. doi: 10.1161/01.cir.0000033824.02722.f7. [DOI] [PubMed] [Google Scholar]
  • 25.Mattace-Raso FU, van der Cammen TJ, Hofman A. Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam Study. Circulation. 2006;113:657–663. doi: 10.1161/CIRCULATIONAHA.105.555235. [DOI] [PubMed] [Google Scholar]
  • 26.Willum-Hansen T, Staessen JA, Torp-Pedersen C. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113:664–670. doi: 10.1161/CIRCULATIONAHA.105.579342. [DOI] [PubMed] [Google Scholar]
  • 27.Waugh J, Keating GM, Plosker GL. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs. Drugs. 2006;2006;6666:85–109. 340–341. doi: 10.2165/00003495-200666010-00005. [published correction appears in. ] [DOI] [PubMed] [Google Scholar]
  • 28.Balas B, Belfort R, Harrison SA. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol. 2007;47:565–570. doi: 10.1016/j.jhep.2007.04.013. [DOI] [PubMed] [Google Scholar]
  • 29.Johansen K. Efficacy of metformin in the treatment of NIDDM: Meta-analysis. Diabetes Care. 1999;22:33–37. doi: 10.2337/diacare.22.1.33. [DOI] [PubMed] [Google Scholar]
  • 30.UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. Lancet. 1998;1998;352352:854–865. 1558. [published correction appears in. ] [PubMed] [Google Scholar]
  • 31.Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol. 2003;1:384–387. doi: 10.1053/s1542-3565(03)00198-8. [DOI] [PubMed] [Google Scholar]
  • 32.Belfort R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307. doi: 10.1056/NEJMoa060326. [DOI] [PubMed] [Google Scholar]
  • 33.Lin HZ, Yang SQ, Chuckaree C. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998–1003. doi: 10.1038/79697. [DOI] [PubMed] [Google Scholar]
  • 34.Marchesini G, Brizi M, Bianchi G. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–894. doi: 10.1016/s0140-6736(01)06042-1. [DOI] [PubMed] [Google Scholar]
  • 35.Uygun A, Kadayifci A, Isik AT. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537–544. doi: 10.1111/j.1365-2036.2004.01888.x. [DOI] [PubMed] [Google Scholar]
  • 36.Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64–66. doi: 10.2337/diacare.19.1.64. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES